Med BioGene Inc. (MBI) is a Canada-based development-stage life science company. The Company is focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. The Company is also focused on managing the license and rights to GeneFx Lung. Its test under development, which is GeneFx Lung (formerly known as LungExpress Dx) is a gene expression-based test to improve upon staging for identifying those patients with early-stage non-small-cell lung cancer (NSCLC).